AMD Invests in Absci to Accelerate AI-Driven Drug Discovery
Generative AI drug creation company Absci Corporation announced on Wednesday a strategic collaboration with AMD to enhance its AI-driven drug discovery capabilities. Through this partnership, Absci will deploy AMD's Instinct accelerators and ROCm software to power critical AI drug discovery workloads, including de novo antibody design models. As part of the partnership, AMD is making a USD 20 million investment in Absci via a private investment in public equity (PIPE),... Read More